Danaher Shows Interest In Acquiring Catalent Valued At Significant Premium: Report

  • Danaher Corporation DHR has reportedly expressed interest in acquiring the contract manufacturer Catalent Inc CTLT.
  • According to the sources, the recent moves by the life science firm valued Catalent at a significant premium. 
  • It's unclear how Catalent will proceed or whether it's receptive to a takeover offer, Bloomberg reported citing people familiar with the matter.
  • Related: Danaher Says 2022 'Another Great Year,' Delivers Around 10% Core Revenue Growth.
  • Danaher and Catalent deal could be one of the largest transactions this year in a sleepy dealmaking market, with volumes down two-thirds globally, the report added. 
  • "As a matter of company policy, Catalent does not comment on market rumors or speculation," the report cited a company spokesperson.
  • Also Read: Catalent-Repligen Merger 'Seems Unlikely,' This Analyst Says.
  • Last year, Catalent received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's NVO obesity drug Wegovy.
  • Catalent provides delivery technologies and development solutions for drugs, biologics, and consumer health products. The manufacturer has gained distinction during the pandemic, helping to produce COVID-19 vaccines and treatments in partnership with companies including Moderna Inc MRNAJohnson & Johnson JNJ, and AstraZeneca Plc AZN.
  • Price Action: CTLT shares are up 25.74% at $70.48 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: Large CapM&ANewsHealth CareRumorsMoversGeneralBriefspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!